Syschem India Closes ₹5.18 Crore Legal Dispute With AP Pharmachem

Image Source: www.syschem.in

Syschem (India) Ltd has officially settled its litigation with AP Pharmachem involving ₹5.18 crore. The case, filed under Section 138 of the Negotiable Instruments Act, was dismissed following payment and a contingent cheque. The resolution marks a key step in stabilizing Syschem’s legal and financial standing.

Legal dispute resolved after months of proceedings

Syschem (India) Ltd has successfully resolved its legal dispute with AP Pharmachem, bringing closure to a case that involved financial claims totaling ₹5.18 crore. The litigation, filed under Section 138 of the Negotiable Instruments Act, was dismissed as withdrawn by the Chief Judicial Magistrate – 1st Class, Taluka Court, Derabassi, on October 22, 2025.

The settlement includes a direct payment of ₹3.95 crore already made by Syschem, along with a contingent cheque of ₹1.23 crore. This contingent amount is subject to exchange rate adjustments for remittance to a Chinese entity, indicating the international scope of the transaction.

Financial and reputational implications

The resolution of this case is expected to improve Syschem’s legal standing and investor confidence. The company, known for manufacturing bulk drugs and specialty chemicals, has been expanding its footprint in both domestic and international markets. Clearing this litigation hurdle allows Syschem to focus on growth and operational efficiency.

Syschem’s recent financial disclosures and rights issue have shown strong investor interest, and the removal of legal overhang could further support its valuation and market performance.

Key highlights of the settlement

- Syschem India settles ₹5.18 crore litigation with AP Pharmachem
- Case dismissed under Section 138 of the Negotiable Instruments Act
- ₹3.95 crore paid directly; ₹1.23 crore issued via contingent cheque
- Contingent amount linked to dollar exchange rate for Chinese remittance
- Settlement order received on October 22, 2025
- Legal clarity expected to boost investor sentiment
- Syschem focuses on bulk drugs, intermediates, and specialty chemicals
- Company recently completed a rights issue to fund expansion

Looking ahead

With the legal dispute behind it, Syschem India is poised to pursue its strategic goals with renewed focus. The company’s commitment to resolving issues swiftly and transparently bodes well for its reputation and future partnerships.

Sources: ScanX News, Chittorgarh, StockInsights.ai